12x6Gy-the Erlangen stereotactic radiotherapy treatment concept result in 95% local progression-free survival for bronchial carcinoma and 83% for pulmonary metastases after 3 years (2018) Lubgan D, Rutzner S, Lambrecht U, Fietkau R Conference contribution RECREATE: Treatment reality for mRCCpatients following first line Pazopanib therapy - a retrospective chart review (2018) Hegele A, Von Der Heyde E, Goebell P, Huebner A, Zengerling F, Klier J, Belz H, et al. Conference contribution Prospective evaluation of geriatric assessment tools as predictors of functional outcome in old patients undergoing major urologic tumor surgery (2018) Kahlmeyer A, Losensky W, Sikic D, Wach S, Ritt M, Goebell P, Keck B, Wullich B Conference contribution Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients (2018) Rot S, Kaune T, Greither T, Kotrba J, Bache M, Al-Nawas B, Vordermark D, et al. Conference contribution Analysis of androgen receptor mRNA expression in urothelial carcinoma of the bladder (2018) Sikic D, Wirtz R, Wach S, Dyrskjot L, Erben P, Bolenz C, Breyer J, et al. Conference contribution A multicenter comparison of PD-L1 protein and mRNA expression in urothelial bladder cancer by immunohistochemistry and RT-qPCR (Checkpoint-Typer(C)): A round robin test by the BRIDGE-Consortium Germany (2018) Eckstein M, Wirtz R, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, et al. Conference contribution A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) (2018) Ahrens M, Scheich S, Goekbuget N, Boleti E, Gruenwald V, Escudier B, Goebell P, et al. Conference contribution Salvage external beam radiation therapy of biochemical relapse after radical prostatectomy: Results and potential role of PET/CT (2018) Rutzner S, Lubgan D, Wullich B, Kuehn R, Kuwert T, Fietkau R Conference contribution P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients (2018) Kappler M, Kotrba J, Kaune T, Bache M, Rot S, Bethmann D, Wichmann H, et al. Conference contribution Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL (2018) Boegemann M, Bedke J, Schostak M, Welslau M, Hering-Schubert C, Wolf T, Schleicher J, et al. Conference contribution